&lt;p&gt;Association of Apolipoprotein e2 Allele with Insulin Resistance and Risk of Type 2 Diabetes Mellitus Among an Admixed Population of Mexico&lt;/p&gt;

González-Aldaco, Karina; Román, Sonia; Torres-Reyes, Luis A.; Panduro, Arturo

doi:10.2147/dmso.s268329

Cited by 11 publications

(6 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The APOE gene product, APOE, is an apolipoprotein that is known to bind lipids and participates in cholesterol metabolism [ 48 ]. Previous studies show that the ApoE e2 allele is associated with insulin resistance and increases the risk of type 2 diabetes mellitus diabetes mellitus (T2DM) [ 49–51 ].…”

Section: Discussionmentioning

confidence: 99%

Bioinformatics analysis of candidate genes and potential therapeutic drugs targeting adipose tissue in obesity

Zhang

Liu

et al. 2021

Adipocyte

View full text Add to dashboard Cite

Obesity is a complex medical condition that affects multiple organs in the body. However, the underlying mechanisms of obesity, as well as its treatment, are largely unexplored . The focus of this research was to use bioinformatics to discover possible treatment targets for obesity. To begin, the GSE133099 database was used to identify 364 differentially expressed genes (DEGs). Then, DEGs were subjected to tissue-specific analyses and enrichment analyses, followed by the creation of a protein-protein interaction (PPI) network and generation of a drug-gene interaction database to screen key genes and potential future drugs targeting obesity. Findings have illustrated that the tissue-specific expression of neurologic markers varied significantly (34.7%, 52/150). Among these genes, Lep, ApoE, Fyn, and FN1 were the key genes observed in the adipocyte samples from obese patients relative to the controls. Furthermore, nine potential therapeutic drugs (dasatinib, ocriplasmin, risperidone, gemfibrozil, ritonavir, fluvastatin, pravastatin, warfarin, atorvastatin) that target the key genes were also screened and selected. To conclude the key genes discovered (Lep, ApoE, Fyn, and FN1), as well as 9 candidate drugs, could be used as therapeutic targets in treating obesity.

show abstract

Section: Discussionmentioning

confidence: 99%

Bioinformatics analysis of candidate genes and potential therapeutic drugs targeting adipose tissue in obesity

Zhang

Liu

et al. 2021

Adipocyte

View full text Add to dashboard Cite

show abstract

“…Then, we assessed whether the APOE isoforms were associated with IR, but no association was observed. Confirming results of previous studies, the relationship between APOE allele frequencies and IR was controversial (23)(24)(25).…”

Section: Discussionmentioning

confidence: 80%

Dissecting the Association of Apolipoprotein E Gene Polymorphisms With Type 2 Diabetes Mellitus and Coronary Artery Disease

Zhang

Zhao

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundApolipoprotein E (APOE) gene mediates lipoprotein clearance and is one of the most studied candidate genes for type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD). This study was performed to determine the association between APOE polymorphisms and T2DM with and without CAD, and its effect on plasma lipid levels in a Chinese population.MethodsA total of 1,414 subjects involving 869 patients and 545 health individuals were recruited. These patients were categorized into three distinct groups: 264 in T2DM group, 401 in CAD group, and 204 in T2DM+CAD group. Logistic regression analysis was used to obtain odds ratio (OR) and 95% confidence interval (CI) in predicting the risk probability of APOE. Besides, a meta-analysis was preformed to integrate an evaluation index to evaluate their associations.ResultsGenotype frequency ratio of genotype ϵ3/4 and allele ϵ4 among the CAD patients with or without T2DM was obviously increased. Compared with ϵ3/3 genotype, the ϵ3/4 genotype had a significant increased risk of CAD (adjusted OR = 1.90, 95% CI = 1.30–2.77) and T2DM+CAD (adjusted OR = 1.95, 95% CI = 1.24–3.08). In the meta-analysis, four studies were included and provided a strong evidence for the APOE ϵ4 mutation elevating the risk of CAD in patients with T2DM (ϵ3/ϵ4+ϵ4/ϵ4 vs. ϵ3/ϵ3, OR = 1.51, 95% CI = 1.13–2.02). In the T2DM group, the plasma levels of low-density lipoprotein cholesterol (LDL-C) showed significant difference among the three APOE isoforms. The high-density lipoprotein cholesterol (HDL-C) levels of CAD patients with ϵ4-bearing genotypes were lower than those with ϵ3/3 genotype.ConclusionsOur results indicate that APOE gene polymorphisms are related to CAD with or without T2DM and have influence on lipid profiles in both T2DM and CAD patients.

show abstract

“…Therefore, APOE may affect the blood lipid metabolic pathway and carotid plaque progression. Second, APOE gene polymorphisms are associated with the development of diabetes ( 27 ), but the underlying mechanism is currently unknown. Studies have speculated that E4 carrier status may affect peripheral and central insulin metabolism ( 28 , 29 ); therefore, differences in blood glucose metabolism can impact arterial plaque development.…”

Section: Discussionmentioning

confidence: 99%

Polymorphisms of the apolipoprotein E gene affect response to atorvastatin therapy in acute ischemic stroke

Zhou

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundPolymorphisms of the apolipoprotein E (APOE) gene are related to the efficacy of statin therapy. The biological functions of the APOE subtypes determine the metabolism of blood plasma lipids and the progression of atherosclerosis. This study aimed to explore the impact of APOE gene polymorphisms on the effect of atorvastatin on lipid regulation and plaque stabilization.MethodsThe study was a prospective cohort study that consecutively included patients with acute ischemic stroke (AIS) in the Department of Neurology, Shanghai Tenth People’s Hospital, from December 2018 to December 2019. The patients were divided into E2, E3, and E4 groups according to their APOE genotype. Atorvastatin (20 mg) was administrated to all patients. Changes in blood lipid levels over 3 months and plaque size and stability over 12 months were analyzed.ResultsWe enrolled 253 consecutive patients with AIS, of whom, 136 had carotid atherosclerotic plaques. Two patients with genotype E2/E4 were excluded. There were 30 patients in the E2 group (12.0%), 191 patients in the E3 group (76.0%), and 30 patients in the E4 group (12.0%). The lowest percentage reduction in low-density lipoprotein cholesterol (LDL-C) was observed in the E4 group (41.2%), while the highest percentage reduction was observed in the E2 group (17.6%). The plaques in the E2 group showed slower progression, while those in the E4 group showed more rapid progression.ConclusionAPOE gene polymorphisms affect the biological functions of atorvastatin. Compared to the ε3 or ε4 allele, the ε2 allele exerted a greater lipid-lowering effect on LDL-C levels, enhanced the ability of atorvastatin to stabilize carotid artery plaques, and slowed carotid artery plaque progression.

show abstract

<p>Association of Apolipoprotein e2 Allele with Insulin Resistance and Risk of Type 2 Diabetes Mellitus Among an Admixed Population of Mexico</p>

Cited by 11 publications

References 51 publications

Bioinformatics analysis of candidate genes and potential therapeutic drugs targeting adipose tissue in obesity

Bioinformatics analysis of candidate genes and potential therapeutic drugs targeting adipose tissue in obesity

Dissecting the Association of Apolipoprotein E Gene Polymorphisms With Type 2 Diabetes Mellitus and Coronary Artery Disease

Polymorphisms of the apolipoprotein E gene affect response to atorvastatin therapy in acute ischemic stroke

Contact Info

Product

Resources

About